More stories

  • in

    China should worry less about its currency

    IT IS EASY to forget that the world’s second-biggest economy is still an emerging market. China’s global clout, its technological prowess in certain fields, and even its low bond yields all distinguish it from the typical member of its asset class. But in at least one respect China resembles a classic emerging market: it retains a palpable fear of floating its currency. Instead China keeps a close eye on the yuan’s value against the dollar and a basket of its trading partners’ currencies, limiting any sharp movements.For most of the past year, it worried that the yuan would float too high. China’s largely successful efforts to stamp out the early variants of covid-19 kept its factories open and its borders closed. That allowed its exports to boom, putting upward pressure on the yuan, even as outbound tourism and other services imports suffered, removing a source of downward pressure. The yuan rose sharply against the basket of trading partners’ currencies and gently against the dollar, which was itself strong.Now China’s fight against the pandemic is instead contributing to the currency’s sudden weakness. Lockdowns stringent enough to hamper manufacturing have been imposed on Shanghai and other cities accounting for over 9% of GDP, according to Gavekal Dragonomics, a consultancy. China’s economic figures for April will “certainly be disastrous”, it says. The war in Ukraine has contributed to outflows from China’s bond and equity markets, as foreigners reassess the risks of investing in countries at geopolitical loggerheads with the West. And as America has lost its fear of the virus, its economy has overheated, forcing the Federal Reserve to raise interest rates. In April the nominal yield on ten-year Treasuries briefly exceeded that on Chinese bonds for the first time since 2010. (Real yields remain much higher in China, where consumer-price inflation is only 1.5%, compared with 8.5% in America’s larger, more “mature” economy.)A weaker yuan is both a reflection of these challenges and one way to cope with them. It will in particular help to shore up China’s exports. But the central bank is not prepared to let the currency be dominated by market forces. It bears the scars of past falls in the yuan, which took on a momentum of their own. On April 25th it said it would cut the amount of reserves banks are required to hold from 9% of their foreign-exchange deposits to 8%. That will release some dollars to the market, alleviating pressure on the yuan. The move also signals the central bank’s displeasure at the speed of its currency’s descent.China’s currency worries may deter the central bank from cutting interest rates to revive growth. That will leave its economy more dependent than ever on fiscal stimulus. At a meeting of the powerful Central Committee for Financial and Economic Affairs on April 26th, Xi Jinping, China’s president, called for more investment in infrastructure, from rural roads and urban drains to smart electricity grids and artificial-intelligence platforms. Citigroup, a bank, forecasts that infrastructure spending could grow by 8% this year. But according to Natixis, another bank, China will not meet its (increasingly forlorn) growth target of around 5.5% unless infrastructure investment grows by almost 18%. Even a conventional emerging market with vast infrastructure needs would struggle to boost spending by that much. China’s fear of floating has inhibited its monetary response to its economic woes. And that has raised fears of its floundering. ■For more expert analysis of the biggest stories in economics, business and markets, sign up to Money Talks, our weekly newsletter. More

  • in

    Slow pain or fast pain? The implications of low investment yields

    IN 1988 STEVE GUTTENBERG, a comic actor, appeared on a British talk show. At one point he was asked why he had not appeared in “Police Academy 5”, having starred in the earlier films. He replied that, in his view, all the important philosophical questions had been addressed in the first four movies.This brings us to the more serious business of investing, and a sequel of a very different kind. Ten years ago Antti Ilmanen, a finance whizz, published “Expected Returns”, a brilliant distillation of investment theory, practice and wisdom. His latest book, “Investing Amid Low Expected Returns”, is an update, taking in a decade’s worth of additional research and data. Mr Ilmanen has read all the books and papers, sorting the good stuff from the junk. He has a gift for explaining clearly and concisely the lessons of this research for investors. The new book is as invaluable a resource as the old one. If it has a fault, it is that it does not quite address all the important philosophical questions. A sequel may be necessary.Start, though, with a recap of the expected-returns framework. There are two sources of return on an investment: income and capital gain. The income on, for instance, a government bond is the interest (or “coupon”) paid once or twice a year. Bond prices and yields move inversely. So when interest rates fall, as they did for much of the past four decades, bond investors enjoy a capital gain. In essence a capital gain of this kind brings forward future returns. You get the income now you were going to get later. But as yields fall ever lower the scope for further capital gains becomes more limited. So low yields imply low expected returns. This bond-like logic holds for other assets—equities, property, private equity and so on. Dividend and rental yields have fallen in response to the secular fall in interest rates. Owners of all kinds of assets have experienced windfall gains. But today’s low yields imply low expected returns in the future.What now? As Mr Ilmanen sees it, low expected returns can materialise through either “slow” or “fast” pain. In the slow-pain scenario, assets remain expensive and investors receive desultory bond coupons, equity dividends and rental receipts for years on end. In the fast-pain scenario yields revert to their higher historical averages. This implies a spell of brutal capital losses followed by fairer returns thereafter. The choice is between well-heeled stagnation and a crash.Mr Ilmanen is too much of an epistemological sceptic to put all his chips on one scenario. He is also too careful an analyst to miss that low inflation made the high-asset-price, low-yield 2010s what they were. Many of the factors that kept a lid on inflation in that decade—globalisation, efficient supply-chain management, tight fiscal policy, an expanding global workforce—are now attenuating or unwinding. Mr Ilmanen’s hunch is that the 2020s will see something of a reversal of the investment trends of the preceding decade. But he generally eschews investing on hunches.Faced with lower expected returns, investors have three courses of action: they can take more risk to reach for higher returns; they can save more; or they can accept reality and play the hand they have been dealt as well as they can. The first approach may increase returns but also makes them more uncertain. Saving more means sacrificing today for the sake of tomorrow, a highly personal choice. Understandably, Mr Ilmanen’s focus is on the third approach. He sets out a chapter-by-chapter analysis of various investment assets and styles. He advises how to put them together in a truly diversified portfolio. Along the way, he explains why market timing is a snare (you end up taking too little risk); what the true appeal of private equity is (not superior returns); and why portfolio insurance will not save you (it is too expensive in the long run).There are shortcomings. A quarter of the 500+ references are from authors affiliated with AQR Capital Management, Mr Ilmanen’s employer. This weighting gives the book a less independent air than “Expected Returns”. Readers would have benefited greatly from a chapter on the implications of low expected returns for different sorts of savers. The fast-pain scenario, for instance, is surely preferable for young savers, to whom the book is dedicated. Perhaps this and other gaps will be filled in “Expected Returns III”. Even Mr Guttenberg has been teasing fans with the prospect of “Police Academy 8”. The big philosophical questions are never truly settled.Read more from Buttonwood, our columnist on financial markets:A requiem for negative government-bond yields (Apr 23rd)The complicated politics of crypto and web3 (Apr 16th)Bonds signal recession. Stocks have been buoyant. What gives? (Apr 9th)For more expert analysis of the biggest stories in economics, business and markets, sign up to Money Talks, our weekly newsletter. More

  • in

    Stocks making the biggest moves premarket: Meta, Teladoc, Pinterest, Qualcomm and more

    Woman holds smartphone with Meta logo in front of a displayed Facebook’s new rebrand logo Meta in this illustration picture taken October 28, 2021.
    Dado Ruvic | Reuters

    Check out the companies making headlines in Thursday premarket trading.
    Meta — Shares of the Facebook parent soared more than 16% in premarket trading after the tech company reported better-than-expected quarterly earnings. Daily active users, which declined in the fourth quarter for the first time, bounced back a bit and topped analysts’ expectations, according to StreetAccount. The rally came despite a revenue miss. Shares were down 48% on the year heading into the results.

    Teladoc — Teladoc’s stock price cratered 43% after the telehealth company reported an earnings miss, as well as disappointing revenue guidance. Teladoc reported a loss of $41.58 per share and generated revenues of $565.4 million. Analysts surveyed by FactSet were expecting a loss of 60 cents per share, and revenues of $568.7 million.
    McDonald’s — Shares of the restaurant chain gained 2% in premarket trading after first quarter revenue came in higher than expected. McDonald’s reported first quarter revenue of $5.67 billion versus the $5.59 billion expected by analysts, according to Refinitiv. The company saw same store sales growth of 3.5% in the U.S. and even higher in international markets.
    Southwest Airlines — The airline stock rose more than 3% in premarket trading after the company delivered an optimistic outlook. Southwest said it expected its second quarter revenue to be up 8% to 12% from the same period in 2019, prior to the pandemic.  For the first quarter, the company reported a loss of 32 cents per share, slightly wider than the 30 cents expected by analysts, according to Refinitiv. First-quarter revenues came in slightly ahead of expectations.
    PayPal — The payment’s company saw shares rise 3.4% in early trading after it beat revenue estimates for the first quarter and posted a slight increase in payments volume. The stock price got a lift despite issuing weak guidance for the second quarter and full year.
    Eli Lilly — The drug maker’s shares gained 3.4% in premarket trading after the company reported results from a clinical trial showing its obesity drug tirzepatide helped patients lose up to 22.5% of their weight. Eli Lilly also reported better-than-expected earnings and revenue for the first quarter and boosted its full-year revenue guidance.

    Pinterest — Shares for the image sharing company surged more than 8% on the back of better-than-expected earnings Wednesday. Pinterest reported adjusted earnings of 10 cents per share and revenues of $575 million. In comparison, analysts polled by Refinitiv expected earnings of 4 cents per share on revenues of $573 million.
    Caterpillar — Shares of the global construction machine maker slid more than 1% despite Caterpillar beating top- and bottom-line estimates during the first quarter. The company earned $2.88 per share excluding items on $13.59 billion in revenue. Analysts were expecting the company to earn $2.60 per share on $13.4 billion in sales, according to estimates compiled by Refinitiv.
    Qualcomm — Shares rallied roughly 7% premarket after a better-than-expected quarterly report. Qualcomm posted adjust earnings per share of $3.21 on revenue of $11.16 billion. Analysts were expected a profit of $2.95 per share on revenue of $10.63 billion, according to StreetAccount.
    ServiceNow — ServiceNow shares jumped more than 8% following the company’s first-quarter earnings report. The platform-as-a-service provider earned $1.73 per share on an adjusted basis and posted $1.72 billion in revenue. Wall Street was expecting $1.70 per share and $1.70 billion in revenue, according to data from StreetAccount.
    — CNBC’s Yun Li, Tanaya Macheel, Hannah Miao, Jesse Pound and Pippa Stevens contributed reporting.

    WATCH LIVEWATCH IN THE APP More

  • in

    Why diesel prices are driving up the cost of everything

    Consumers notice spiking gasoline prices every time they drive to the pump. But energy industry analysts say the current spike in diesel prices is historic — and is pushing up the cost of all kinds of goods.
    Diesel prices are hovering around all-time highs, forced upward by the same circumstances that have fueled gasoline’s rise.

    “The price of diesel is probably the bigger headline here,” said Patrick De Haan, head of petroleum analysis for GasBuddy.
    Nearly everything people buy is at some point freighted in a vehicle powered by a diesel engine. Ships and barges, trains, trucks and even some airplanes run on diesel fuel.
    Diesel hit an all-time high of $5.135 on March 12, according to AAA. As of April 27, the price was only slightly lower at $5.093.
    That increase is hitting consumer prices hard, says Moody’s Analytics chief economist Mark Zandi, who notes that diesel has had a significant factor in rising inflation.
    It is also hitting truckers hard. Truckers who used to spend about $10,000 a week on fuel now are spending closer to $18,000 a week.

    Freight industry analysts suspect the very fragmented and volatile trucking industry will likely experience another severe recession. Some are even calling it a “bloodbath.”
    “We see when fuel surges as much as it has over the past couple of months, that’s usually when we see a lot of trucking bankruptcies follow,” said Craig Fuller, founder and CEO of Freightwaves, an industry data tracker.
    That amounts to bad news for the nearly 2 million trucking companies in America, the vast majority of which are small businesses with just a handful of trucks.
    “These small operators that live essentially on the cash flow of their trucking operations are not prepared and don’t have the balance sheets or the cash position to absorb these instantaneous shocks to their cash flow,” Fuller said.
    Watch the video to learn more.

    WATCH LIVEWATCH IN THE APP More

  • in

    Southwest Airlines keeps 2022 profit forecast as bookings and fares outpace higher costs

    Southwest Airlines posted a net loss in the first quarter.
    The airline expects second-quarter revenue to top 2019 even though it will fly less.
    Southwest expects higher fares to outpace a jump in labor, airport and fuel costs.

    A Southwest Airlines jet lands at Midway International Airport on January 28, 2021 in Chicago, Illinois.
    Scott Olson | Getty Images

    Southwest Airlines reiterated its forecast for second-quarter and 2022 profits as bookings and fares outpace a jump in labor, fuel and airport costs.
    The Dallas-based carrier expects second-quarter revenue growth of 8% to 12% over the $5.9 billion it brought in during the same quarter of 2019, even though it plans to fly 7% less than three years ago.

    Southwest’s shares rose more than 3% in premarket trading.
    The profit forecast echoes outlooks from United Airlines, Delta Air Lines and American Airlines earlier this month and points to strong travel demand and a willingness among consumers to pay up for seats despite the sharpest spike in consumer prices since the early 1980s.
    For the full year, Southwest said it is maintaining plans to fly 4% less than in 2019. Airlines have compared results with 2019 to show progress in their pandemic recoveries.
    Carriers have been forced to pull back capacity as staffing shortages exacerbated flight cancellations and delays over the past year. JetBlue Airways, for example, on Tuesday said it was slashing its growth plan for 2022 by as much as 5% from a previous plan to expand flying up to 15%, sending shares tumbling.
    Southwest swung to a $278 million net loss for the first quarter, down from a $116 million profit a year earlier, on $4.7 billion in revenue as it struggled with a surge in omicron infections.

    WATCH LIVEWATCH IN THE APP More

  • in

    Bitcoin adopted as legal tender by African country — the second to do so after El Salvador

    Central African Republic lawmakers voted unanimously to pass a bill legalizing crypto.
    Bitcoin will be considered legal tender alongside the regional Central African CFA franc.
    The CAR is the second nation in the world to make bitcoin legal tender. El Salvador did so last year.

    Bitcoin is a volatile asset, and has been known to swing more than 10% higher or lower in a single day.
    Jakub Porzycki | Nurphoto | Getty Images

    The Central African Republic has become the second country in the world to adopt bitcoin as official currency, after El Salvador took the same step last year.
    Lawmakers in the CAR’s parliament voted unanimously to pass a bill legalizing bitcoin and other cryptocurrencies, according to a statement from the presidency.

    Bitcoin will be considered legal tender alongside the regional Central African CFA franc.
    Obed Namsio, chief of staff to President Faustin-Archange Touadera, called the move “a decisive step toward opening up new opportunities for our country,” according to Reuters.

    The CAR is rich in diamonds, gold and other valuable minerals, but ranks as one of the world’s poorest and least-developed countries.
    Roughly 71% of CAR’s 5.4 million inhabitants were living below the international poverty line in 2020, according to the World Bank. And just 11% of the CAR’s population have access to the internet.
    The country, which is landlocked in the heart of Africa, has been gripped by political instability and violence for years.

    The move to consider bitcoin legal tender received praise from the crypto community, and was hailed as another step toward mainstream adoption of cryptocurrencies.
    But it can also be viewed as controversial. There were protests in El Salvador after the country introduced the Bitcoin Law, and the country faced criticism from the International Monetary Fund.
    The IMF has urged El Salvador to drop bitcoin as legal tender, raising concerns over the risks it poses to financial stability and consumer protection.

    Read more about cryptocurrencies from CNBC Pro

    Bitcoin is a notoriously volatile asset, which raises questions about its role as a standard method of payment. It was last trading at around $39,686 Thursday, down 6% in the last 24 hours. The cryptocurrency has lost around 42% of its value since an all-time peak above $68,000 in November.
    Many Western governments have raised the alarm about the potential use of cryptocurrencies by Russia to evade sanctions amid the country’s invasion of Ukraine.
    CAR is a close ally of Russia, with Russian mercenaries having provided direct assistance to the government, according to the UN.

    Experts suggested the move could help small countries like the CAR reduce their dependence on the U.S. dollar for global trade.
    Ransu Salovaara, CEO of crypto platform Likvidi, noted that the dollar has been the global oil currency since the 1950s.
    “Oil dependence is a major issue now, because of the Ukraine and the SWIFT banking ban, so global, unstoppable cryptocurrencies like bitcoin can really shine,” he added.

    WATCH LIVEWATCH IN THE APP More

  • in

    Moderna asks FDA to authorize Covid vaccine for kids under 6 years old

    The two-dose vaccine was about 51% effective against infection from the omicron variant in children under 2 years old and about 37% effective among 2- to 5-year-old kids, according to Moderna.
    Dr. Paul Burton, Moderna’s chief medical officer, said the vaccines induced high levels of antibodies in the kids, which should correlate to a high level of protection against severe illness.
    The FDA has promised to move quickly to authorize shots for infants, toddlers and preschoolers once the vaccine makers submit complete applications.

    With her husband Stephen by her side Erin Shih hugs her children Avery 6, and Aidan, 11, after they got their second Moderna COVID-19 vaccines at Kaiser Permanente Los Angeles Medical Center on Friday, June 25, 2021.
    Sarah Reingewirtz | MediaNews Group | Getty Images

    Moderna on Thursday asked the Food and Drug Administration to authorize its Covid vaccine for children ages 6 months to 5 years old.
    The vaccine was about 51% effective against infection from the omicron variant in children under 2 years old and about 37% effective among 2- to 5-year-old kids, according to a company press release. Dr. Paul Burton, Moderna’s chief medical officer, said those levels are similar to two-dose protection for adults.

    The protection Moderna’s vaccine provides against infection has declined substantially from the high-water mark of 90% effectiveness when the shots first rolled out. The omicron variant, which has more than 30 mutations, is adept at evading the antibodies that block the virus from invading human cells.
    However, Burton said children under 6 years old who receive two doses should have high levels of protection against severe illness. Adults have about 1,000 units of antibody after two shots with at least 70% protection against severe disease, while children in the study had 1,400 to 1,800 units of antibody after two doses, he said.
    “What we know is that those levels of antibody will translate into very high protection against severe disease and hospitalization,” Burton said. None of the children in the study were hospitalized with Covid, he added.
    Moderna plans to study a booster dose for children under age 6 with a redesigned shot that targets omicron as well as the original strain of the virus that emerged in Wuhan, China. One of the reasons vaccine effectiveness against infection has declined so steeply is because the current shots are still targeting the Wuhan strain, even though the virus has evolved dramatically since it was first discovered in late 2019.
    If authorized by the FDA, children under age 6 would receive two 25-microgram shots, a much smaller dose than the 100 microgram shots currently approved by the FDA as a primary vaccination series for adults. Burton said the safety profile for kids is reassuring, with 0.2% of the children developing fevers of 103 degrees Fahrenheit, or 40 degrees Celsius. About 17% of kids under 2 years old developed a fever of 100 degrees Fahrenheit while slightly more than 14% of kids from 2 to 6 years old developed such a fever, according to a press release Moderna issued in March on its study results.

    Kids under 6 years old are in the only age group in the U.S. that is not yet eligible for vaccination. The FDA has promised to move quickly to authorize shots for infants, toddlers and preschoolers once the vaccine makers submit complete applications.
    Dr. Peter Marks, who heads the FDA office responsible for vaccines, told the Senate health committee this week that the drug regulator’s committee of independent advisors will meet to fully review the data.
    “We will proceed with all due speed once we have complete applications,” Marks said. He told the committee that the FDA will publish a timeline in the next week for advisory committee meetings on several emergency-use applications. The FDA is in the process of clearing several potential dates for the committee to meet in June, according to a person familiar with matter.
    Parents have been waiting for months for a way to protect their children against the virus. During the winter omicron wave, children younger than 5-years-old were hospitalized with Covid at five times the rate of the pandemic’s peak, when delta was dominant, according to the Centers for Disease Control and Prevention. About 75% of children under 11 years old had been infected with Covid as of February, according to data released by the CDC this week.
    The FDA had originally sought to fast track authorization of Pfizer’s Covid vaccine for children under age 5 in February by clearing the first two doses of the three-shot vaccine. However, Pfizer decided to postpone its application and wait for data on the third shot, because the results from the first two doses weren’t good enough.
    Pfizer CEO Albert Bourla, in a podcast interview, said the first two shots only had 30% to 40% efficacy, but he expects the third dose to significantly improve protection. The vaccine has a three-microgram dosing level, much smaller than the 30-micrograms used for adults.
    Bourla said he hopes Pfizer’s vaccine will receive FDA authorization in June.

    CNBC Health & Science

    Read CNBC’s latest global coverage of the Covid pandemic:

    WATCH LIVEWATCH IN THE APP More

  • in

    Merck sold $3.2 billion of its Covid oral antiviral treatment, driving first-quarter revenue growth

    Merck beat Wall Street estimates for its top and bottom lines, reporting earnings of $2.14 per share on $15.9 billion in revenue.
    The company raised its 2022 earnings guidance to between $7.24 and $7.36 per share on $56.9 billion to $58.1 billion in revenue.
    Merck’s growth was driven by its Covid treatment molnupiravir, its cancer treatment Keytruda, and its HPV vaccine Gardasil.

    Medicine pill is seen with Merck logo and words ‘Molnupiravir’ and ‘COVID-19′ displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021.
    Jakub Porzycki | NurPhoto | Getty Images

    Merck sold $3.2 billion of its oral antiviral treatment for Covid in the first quarter, fueling the company’s strong revenue growth.
    Merck soundly beat Wall Street profit and revenue forecasts, reporting earnings of $2.14 per share on $15.9 billion in revenue. The company raised its 2022 earnings guidance to between $7.24 and $7.36 per share on $56.9 billion to $58.1 billion in revenue. It previously projected earnings per share between $7.12 to $7.27 on revenue of between $56.1 to $57.6 billion.

    Merck’s stock rose nearly 2% in premarket trading.
    Here’s how Merck performed compared with what Wall Street expected, based on analysts’ average estimates compiled by Refinitiv:

    Adjusted earnings: $2.14 per share vs. $1.83 expected
    Revenue: $15.9 billion vs. $14.68 billion

    Merck’s Covid treatment, molnupiravir, has sold well since the Food and Drug Administration authorized the pill in December. It made up 20% of the company’s first-quarter revenue. However, Merck lowered its 2022 sales guidance for molnupiravir to between $5 billion and $5.5 billion, down from its previous outlook of $5 billion to $6 billion. Merck splits profits from the pill equally with its partner Ridgeback Therapeutics.
    Overall, pharmaceutical sales grew 50% to $14.1 billion compared to first quarter 2021. Keytruda, an antibody treatment used against several types of cancer, booked sales of $4.8 billion, 23% growth over the same quarter last year. Gardasil, Merck’s HPV vaccine, grew 59% to $1.46 billion compared to 2021.
    This is a developing story. Please check back for updates.

    CNBC Health & Science

    Read CNBC’s latest global coverage of the Covid pandemic:

    WATCH LIVEWATCH IN THE APP More